Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pralubactam
- Development stage
- Phase 3
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Pralubactam (FL058) is a novel small molecule beta-lactamase inhibitor developed by Qilu Pharmaceutical. It is designed to be administered intravenously in combination with the carbapenem antibiotic meropenem (as Meropenem-Pralubactam or Meropenem/FL058) to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). By inhibiting beta-lactamase enzymes that would otherwise degrade carbapenem antibiotics, pralubactam restores the efficacy of meropenem against resistant bacterial strains. The combination is currently in Phase 3 clinical development for several indications, including hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated intra-abdominal infections (cIAI), and complicated urinary tract infections (cUTI).
- Other names
- pralubactampralurbactam
02
Targets
Neuraminidase
Beyond the preview
Go deeper on pralubactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pralubactam.